Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: A pilot study

European Radiology

Volumn 22, Issue 6, 2012, Pages 1214-1223

  Sieghart, Wolfgang ^a   Pinter, Matthias ^a   Reisegger, Michael ^a   Müller, Christian ^a   Ba Ssalamah, Ahmed ^a   Lammer, Johannes ^a   Peck Radosavljevic, Markus ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chemoembolisation; Hepatocellular carcinoma; Liver cancer; Sorafenib; TACE

Indexed keywords

BILIRUBIN; DOXORUBICIN; GLUCOSE; IODINATED POPPYSEED OIL; SORAFENIB;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; ARTIFICIAL EMBOLISM; BILIRUBIN BLOOD LEVEL; BLEEDING; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DECOMPENSATED LIVER CIRRHOSIS; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERBILIRUBINEMIA; HYPOGLYCEMIA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER FUNCTION; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN MANIFESTATION; SURVIVAL RATE; TRANSARTERIAL CHEMOEMBOLISATION; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT; WEIGHT REDUCTION;

AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; PILOT PROJECTS; PYRIDINES; TREATMENT OUTCOME;

EID: 84861526724     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-011-2368-z     Document Type: Article

References (37)

1. Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics 2002. CA Cancer J Clin 55:74-108
2. Hucke F, Sieghart W, Schöniger-Hekele M, Peck-Radosavljevic M, Müller CC (2011) Clinical characteristics of patients with hepatocellular carcinoma in Austria - is there a need for a structured screening program? Wien Klin Wochenschr 123:542-551
3. Peck-Radosavljevic M, Sieghart W, Kölblinger C et al (2011) Austrian Joint ÖGGH-ÖGIR-ÖGHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma. Wien Klin Wochenschr. doi:10.1007/ s00508-011-0056-2
4. Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421-430 (Pubitemid 32844200)
5. Bruix J, ShermanM(2005) Management of hepatocellular carcinoma. Hepatology 42:1208-1236 (Pubitemid 43112690)
6. Llovet JM, Brú C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19:329-438
7. Raoul JL, Sangro B, Forner A et al (2011) Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 37:212-220
8. Llovet JM, Real MI, Montaña X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734-1739 (Pubitemid 34607087)
9. Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164-1171 (Pubitemid 34454013)
10. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429-442 (Pubitemid 36152543)
11. Llovet JM, Ricci S, Mazzaferro Vet al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390
12. Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25-34
13. Abou-Alfa GK, Johnson P, Knox JJ et al (2010) Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 304:2154-2160
14. Wilhelm S, Carter C, Lynch M et al (2006) Discovery and development of sorafenib: amultikinase inhibitor for treating cancer. Nat Rev Drug Discov 5:835-844 (Pubitemid 44480537)
15. Wilhelm SM, Adnane L, Newell P et al (2008) Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 7:3129-3140
16. Liu L, Cao Y, Chen C et al (2006) Sorafenib blocks the RAF/MEK/ ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66:11851-11858 (Pubitemid 46094197)
17. Sergio A, Cristofori C, Cardin R et al (2008) Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 103:914-921 (Pubitemid 351506379)
18. Li X, Feng GS, Zheng CS et al (2004) Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol 10:2878-2882 (Pubitemid 39303010)
19. Dufour JF, Hoppe H, Heim MH et al (2010) Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist 15:1198-1204
20. Chung Y, Kim B, Chen C et al (2010) Study in Asia of the combination of transcatheter arterial chemoembolization (TACE) with sorafenib in patients with hepatocellular carcinoma (HCC) trial (START): second interim safety and efficacy analysis. J Clin Oncol 28:Abstract 4026.
21. Erhardt A, Kolligs FT, Dollinger MM et al (2009) First-in-men demonstration of sorafenib plus TACE for the treatment of advanced hepatocellular carcinoma (SOCRATES trial). Hepatology 50: Abstract 1675.
22. Reyes D, Azad N, Koteish A et al (2010) Phase II trial of sorafenib combined with doxorubicin eluting bead-transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: Interim safety analysis. SIR S56:Abstract 141.
23. Reyes DK, Azad NS, Koteich A et al (2010) Phase II trial of sorafenib combined with doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) for patients with unresectable hepatocellular carcinoma (HCC): interim safety and efficacy analysis. Presented at American Society of Clinical Oncology Gastrointestinal Cancers Symposium: Abstract 254.
24. Strebel BM, Dufour JF (2008) Combined approach to hepatocellular carcinoma: a newtreatment concept for nonresectable disease. Expert Rev Anticancer Ther 8:1743-1749
25. Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6-25 (Pubitemid 44900485)
26. Peck-Radosavljevic M, Greten TF, Lammer J et al (2010) Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 22:391-398
27. Llovet JM, Di Bisceglie AM, Bruix J et al (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698-711
28. Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52-60
29. Abou-Alfa GK, Schwartz L, Ricci S et al (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293-4300 (Pubitemid 46630787)
30. Richly H, Schultheis B, Adamietz IA et al (2009) Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. Eur J Cancer 45:579-587
31. Lammer J, Malagari K, Vogl T et al (2009) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33:41-52
32. Varela M, Real MI, Burrel M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46:474-481 (Pubitemid 46201723)
33. Vogl TJ, Trapp M, Schroeder H et al (2000) Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center. Radiology 214:349-357 (Pubitemid 30077688)
34. Saccheri S, Lovaria A, Sangiovanni A et al (2002) Segmental transcatheter arterial chemoembolization treatment in patients with cirrhosis and inoperable hepatocellular carcinomas. J Vasc Interv Radiol 13:995-999 (Pubitemid 35231855)
35. Grieco A, Marcoccia S, Miele L et al (2003) Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival. Hepatogastroenterology 50:207-212 (Pubitemid 36182969)
36. Farinati F, De Maria N, Marafin C et al (1996) Unresectable hepatocellular carcinoma in cirrhosis: survival, prognostic factors, and unexpected side effects after transcatheter arterial chemoembolization. Dig Dis Sci 41:2332-2339
37. Kloeckner R, Otto G, Biesterfeld S, Oberholzer K, Dueber C, Pitton MB (2010) MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 33:532-540